Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.

MLA

Jhaveri, K. L., et al. “Ado-Trastuzumab Emtansine (T-DM1) in Patients with HER2-Amplified Tumors Excluding Breast and Gastric/Gastroesophageal Junction (GEJ) Adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Subprotocol Q.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 30, no. 11, Nov. 2019, pp. 1821–30. EBSCOhost, https://doi.org/10.1093/annonc/mdz291.

APA

Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Conley, B. A., Arteaga, C. L., Harris, L. N., O’Dwyer, P. J., Chen, A. P., & Flaherty, K. T. (2019). Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 30(11), 1821–1830. https://doi.org/10.1093/annonc/mdz291

Chicago

Jhaveri, K L, X V Wang, V Makker, S-W Luoh, E P Mitchell, J A Zwiebel, E Sharon, et al. 2019. “Ado-Trastuzumab Emtansine (T-DM1) in Patients with HER2-Amplified Tumors Excluding Breast and Gastric/Gastroesophageal Junction (GEJ) Adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Subprotocol Q.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 30 (11): 1821–30. doi:10.1093/annonc/mdz291.